Forest Laboratories and Geodon Richter PIc announced results from its Phase 3 study of cariprazine (RGH-188) for the treatment of patients with acute mania associated with bipolar I disorder.
The FDA has notified healthcare professionals and patients that serious allergic reactions have been reported with the use of Saphris (asenapine; Merck).
The FDA has notified healthcare professionals and patients that Celexa (citalopram hydrobromide; Forest) should no longer be used at doses >40mg/day because it can cause arrhythmias (eg, QT prolongation and torsades de pointes).
Forest Laboratories announced results from its Phase 3 study of levomilnacipran for the treatment of adults with major depressive disorder (MDD).
Investigators reporting at the American Pain Society’s 30th Annual Scientific Meeting shared results of their study regarding musculoskeletal pain in sufferers of post-traumatic stress disorder (PTSD).
Greenstone announced a recall of medicines labeled with the Lot # FI0510058-A because they may be mislabeled.
Repligen announced results from its Phase 2b study of RG2417 for bipolar depression.
AstraZeneca and Targacept announced the initiation of a Phase2b clinical trial of TC-5214 as a “switch” monotherapy treatment for patients with MDD who do not respond adequately to initial antidepressant therapy.
Rexahn Pharmaceuticals announced that it has enrolled the first patient in its Phase 2b trial of Serdaxin to treat major depressive disorder (MDD).
Merck announced that Saphris (asenapine sublingual tablets) has been approved for two additional indications: 1) the maintenance treatment of schizophrenia and 2) as adjunctive therapy with either lithium or valproate for the acute treatment of manic or mixed episodes associated with bipolar I disorder in adults.
